select a format

Single User License
USD 3500 INR 227465
Site License
USD 7000 INR 454930
Corporate User License
USD 10500 INR 682395

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0503TDB
  • |
  • Pages: 71
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Pipeline Review, H2 2016', provides in depth analysis on Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted pipeline therapeutics.

The report provides comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview 6

Therapeutics Development 7

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Products under Development by Stage of Development 7

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Products under Development by Therapy Area 8

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Products under Development by Indication 9

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Products under Development by Companies 13

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Companies Involved in Therapeutics Development 22

Karyopharm Therapeutics, Inc. 22

Stemline Therapeutics, Inc. 24

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Drug Profiles 25

KPT-251-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

KPT-276-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

KPT-350-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

KPT-8602-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

selinexor-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

SL-801-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

verdinexor-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Dormant Projects 51

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Discontinued Products 54

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)-Featured News & Press Releases 55

Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting 55

Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 56

Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements 57

Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting 58

Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 59

Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma 60

May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting 60

May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting 61

May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 63

Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury 63

Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus 64

Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting 65

Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting 67

Mar 04, 2016: Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology 68

Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 (Contd..1) 15

Products under Development by Companies, H2 2016 (Contd..2) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Karyopharm Therapeutics, Inc., H2 2016 22

Pipeline by Stemline Therapeutics, Inc., H2 2016 24

Dormant Projects, H2 2016 51

Dormant Projects (Contd..1), H2 2016 52

Dormant Projects (Contd..2), H2 2016 53

Discontinued Products, H2 2016 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Karyopharm Therapeutics, Inc.

Stemline Therapeutics, Inc.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Therapeutic Products under Development, Key Players in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Therapeutics, Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Pipeline Overview, Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Pipeline, Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com